Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nitin Roper

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
EMBO Molecular Medicine|July 26, 2023
ATR inhibition augments the efficacy of lurbinectedin in small-cell lung cancerChristopher W Schultz, Yang Zhang, Rajaa Elmeskini, et al.
Biorxiv : the Preprint Server for Biology|October 17, 2024
Identification of DLK1, a Notch ligand, as an immunotherapeutic target and regulator of tumor cell plasticity and chemoresistance in adrenocortical carcinomaNai-Yun Sun, Suresh Kumar, Yoo Sun Kim, et al.
EMBO Molecular Medicine|February 17, 2024
Author Correction: ATR inhibition augments the efficacy of lurbinectedin in small-cell lung cancerChristopher W Schultz, Yang Zhang, Rajaa Elmeskini, et al.
Nature Communications|June 23, 2023
Targeting neddylation sensitizes colorectal cancer to topoisomerase I inhibitors by inactivating the DCAF13-CRL4 ubiquitin ligase complexYilun Sun, Simone A Baechler, Xiaohu Zhang, et al.
Cell Reports. Medicine|June 3, 2020
Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung CancerNitin Roper, Anna-Leigh Brown, Jun S Wei, et al.
Nature Communications|July 2, 2025
Identification of the Notch ligand DLK1 as an immunotherapeutic target and regulator of tumor cell plasticity and chemoresistance in adrenocortical carcinomaNai-Yun Sun, Suresh Kumar, Yoo Sun Kim, et al.
The Journal of Clinical Investigation|July 8, 2025
NOTCH1 reverses immune suppression in small cell lung cancer through reactivation of STINGYoo Sun Kim, Barzin Y Nabet, Briana N Cortez, et al.
Cancer Discovery|January 30, 2023
Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and Is Associated with Worse OutcomesLőrinc Sándor Pongor, Christopher W Schultz, Lorenzo Rinaldi, et al.
Nature Genetics|December 4, 2023
The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistanceDeborah R Caswell, Philippe Gui, Manasi K Mayekar, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
EMBO Molecular Medicine|July 26, 2023
ATR inhibition augments the efficacy of lurbinectedin in small-cell lung cancerChristopher W Schultz, Yang Zhang, Rajaa Elmeskini, et al.
Biorxiv : the Preprint Server for Biology|October 17, 2024
Identification of DLK1, a Notch ligand, as an immunotherapeutic target and regulator of tumor cell plasticity and chemoresistance in adrenocortical carcinomaNai-Yun Sun, Suresh Kumar, Yoo Sun Kim, et al.
EMBO Molecular Medicine|February 17, 2024
Author Correction: ATR inhibition augments the efficacy of lurbinectedin in small-cell lung cancerChristopher W Schultz, Yang Zhang, Rajaa Elmeskini, et al.
Nature Communications|June 23, 2023
Targeting neddylation sensitizes colorectal cancer to topoisomerase I inhibitors by inactivating the DCAF13-CRL4 ubiquitin ligase complexYilun Sun, Simone A Baechler, Xiaohu Zhang, et al.
Cell Reports. Medicine|June 3, 2020
Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung CancerNitin Roper, Anna-Leigh Brown, Jun S Wei, et al.
Nature Communications|July 2, 2025
Identification of the Notch ligand DLK1 as an immunotherapeutic target and regulator of tumor cell plasticity and chemoresistance in adrenocortical carcinomaNai-Yun Sun, Suresh Kumar, Yoo Sun Kim, et al.
The Journal of Clinical Investigation|July 8, 2025
NOTCH1 reverses immune suppression in small cell lung cancer through reactivation of STINGYoo Sun Kim, Barzin Y Nabet, Briana N Cortez, et al.
Cancer Discovery|January 30, 2023
Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and Is Associated with Worse OutcomesLőrinc Sándor Pongor, Christopher W Schultz, Lorenzo Rinaldi, et al.
Nature Genetics|December 4, 2023
The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistanceDeborah R Caswell, Philippe Gui, Manasi K Mayekar, et al.
Pageof 5